Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Stock analysts at Svb Leerink boosted their FY2022 earnings estimates for shares of Jazz Pharmaceuticals in a report issued on Tuesday, November 5th. Svb Leerink analyst A. Fadia now anticipates that the specialty pharmaceutical company will post earnings per share of $25.40 for the year, up from their prior forecast of $25.33. Svb Leerink also issued estimates for Jazz Pharmaceuticals’ FY2023 earnings at $21.22 EPS.
A number of other analysts also recently weighed in on JAZZ. Barclays reissued a “buy” rating and set a $182.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday. Oppenheimer set a $176.00 target price on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, September 26th. Piper Jaffray Companies downgraded shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $205.00 to $142.00 in a research report on Wednesday, August 21st. HC Wainwright reissued a “hold” rating and set a $147.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, August 8th. Finally, ValuEngine raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the stock. Jazz Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $167.33.
NASDAQ:JAZZ traded up $4.18 on Friday, reaching $130.14. 747,500 shares of the stock traded hands, compared to its average volume of 551,936. The firm has a market capitalization of $7.24 billion, a price-to-earnings ratio of 10.63, a price-to-earnings-growth ratio of 1.57 and a beta of 1.09. The company’s 50 day moving average is $124.77 and its 200-day moving average is $131.70. The company has a current ratio of 3.71, a quick ratio of 3.52 and a debt-to-equity ratio of 0.58. Jazz Pharmaceuticals has a 1-year low of $113.52 and a 1-year high of $154.44.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share for the quarter, beating analysts’ consensus estimates of $3.19 by $0.91. The business had revenue of $537.70 million during the quarter, compared to the consensus estimate of $523.92 million. Jazz Pharmaceuticals had a net margin of 29.61% and a return on equity of 28.57%. The company’s revenue for the quarter was up 14.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.58 EPS.
In related news, CEO Bruce C. Cozadd sold 500 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $130.00, for a total value of $65,000.00. Following the transaction, the chief executive officer now directly owns 311,855 shares in the company, valued at approximately $40,541,150. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Paul Treacy sold 4,371 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $137.40, for a total value of $600,575.40. The disclosure for this sale can be found here. Insiders have sold a total of 5,371 shares of company stock worth $730,575 over the last 90 days. Company insiders own 4.30% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the stock. Machina Capital S.A.S. bought a new position in shares of Jazz Pharmaceuticals in the 2nd quarter worth $29,000. Signaturefd LLC lifted its stake in Jazz Pharmaceuticals by 56.3% during the 2nd quarter. Signaturefd LLC now owns 200 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 72 shares in the last quarter. MUFG Americas Holdings Corp bought a new position in Jazz Pharmaceuticals during the 3rd quarter valued at $29,000. Captrust Financial Advisors lifted its stake in Jazz Pharmaceuticals by 120.0% during the 2nd quarter. Captrust Financial Advisors now owns 220 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 120 shares in the last quarter. Finally, Stonebridge Capital Advisors LLC bought a new position in Jazz Pharmaceuticals during the 2nd quarter valued at $37,000. Institutional investors own 87.71% of the company’s stock.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Recommended Story: What are no-load funds?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.